Patterns of CNS Failures in Relapse/Refractory Large B-Cell Lymphoma (LBCL) Patients with Secondary CNS Disease Following Chimeric Antigen Receptor T-Cell (CAR T) Therapy
Nakashima J, Khatri V, Cruz-Chamorro R, Zhou J, Patra P, Gaballa S, Khimani F, Mirza S, Shah B, Saeed H, Chavez J, Locke F, Nishihori T, Liu H, Dong N, Lazaryan A, Robinson T, Freeman C, Jain M, Figura N. Patterns of CNS Failures in Relapse/Refractory Large B-Cell Lymphoma (LBCL) Patients with Secondary CNS Disease Following Chimeric Antigen Receptor T-Cell (CAR T) Therapy. International Journal Of Radiation Oncology • Biology • Physics 2024, 120: e646-e647. DOI: 10.1016/j.ijrobp.2024.07.1421.Peer-Reviewed Original ResearchLarge B-cell lymphomaSecondary CNS lymphomaB-cell lymphomaCNS failureCNS recurrenceCNS diseaseCNS lymphomaCAR-TOverall survivalBridging therapyCNS diagnosisRelapsed/refractory large B-cell lymphomaChimeric antigen receptor T cellsCAR-T cell trialsPattern of failure analysisCAR-T cell therapyMedian age of patientsClinical outcomes of patientsCNS-only progressionSystemic disease recurrenceT-cell therapyCAR-T therapyCytokine-release syndromePatterns of recurrenceKaplan-Meier methodBSLM-03 BRANCHED-CHAIN KETO ACIDS PROMOTE AN IMMUNE-SUPPRESSIVE AND NEURODEGENERATIVE MICROENVIRONMENT IN LEPTOMENINGEAL DISEASE
Khaled M, Ren Y, Kundalia R, Alhaddad H, Chen Z, Wallace G, Evernden B, Ospina O, Hall M, Liu M, Darville L, Izumi V, Chen Y, Pilon-Thomas S, Stewart P, Koomen J, Corallo S, Jain M, Robinson T, Locke F, Forsyth P, Smalley I. BSLM-03 BRANCHED-CHAIN KETO ACIDS PROMOTE AN IMMUNE-SUPPRESSIVE AND NEURODEGENERATIVE MICROENVIRONMENT IN LEPTOMENINGEAL DISEASE. Neuro-Oncology Advances 2024, 6: i5-i5. PMCID: PMC11296858, DOI: 10.1093/noajnl/vdae090.014.Peer-Reviewed Original ResearchChimeric antigen receptorLeptomeningeal diseaseBranched-chain keto acidsSodium phenylbutyrateCerebrospinal fluidSurvival outcomesT cellsBreast cancerEfficacy of CAR T-cell therapyAnti-tumor immune environmentCAR-T cell therapyMurine model of breast cancerResponse to immune therapyModel of breast cancerFunction of T lymphocytesT-cell therapyDysfunctional T cellsComprehensive multi-omics analysisPoor survival outcomesCerebrospinal fluid of patientsAnalysis of cerebrospinal fluidPreclinical rationaleImmune therapyImmune environmentNeurological deterioration